Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Agxx Intellectual Property Holding GmbH manages a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently shows 1 pending office action. This action represents the company's active prosecution efforts at the patent office, indicating a focused engagement with examiners within this specific field.
The prosecution is concentrated under 1 distinct examiner and 1 distinct art unit. This lack of distribution across multiple units or examiners suggests that the pending matter falls within a specific technical niche. For the applicant, this means that the prosecution strategy is currently tied to the interpretation and procedural habits of the assigned personnel and their specific art unit.
BROWE, DAVID is the busiest examiner for this portfolio, with 1 busiest examiner pending office action. Because the total number of pending office actions is 1, this examiner is responsible for all current activity. The focus on 1 distinct art unit and 1 distinct examiner ensures that the company's current patent prosecution is centralized rather than fragmented across different personnel.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VU, JAKE MINH | 1 | 41.0% | +27.0% |
| BROWE, DAVID | 1 | 26.8% | +27.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17926580 | PARTICULATE ANTIMICROBIAL HYBRID SYSTEM | BROWE, DAVID | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17926583 | BIOACTIVE COMPOSITION FOR KILLING CELLS | VU, JAKE MINH | — |
| 17926580 | PARTICULATE ANTIMICROBIAL HYBRID SYSTEM | BROWE, DAVID | — |
| Art Unit | Apps |
|---|---|
| 1618 | 1 |
| 1617 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17926583 | BIOACTIVE COMPOSITION FOR KILLING CELLS | VU, JAKE MINH | 1618 | §102Other | Final Rejection | — | Pending | Nov 28, 2022 |
| 17926580 | PARTICULATE ANTIMICROBIAL HYBRID SYSTEM | BROWE, DAVID | 1617 | §103§112Other | Non-Final OA | — | Pending | Nov 19, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialAgxx Intellectual Property Holding GmbH has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Jake Minh Vu has the most, with 1 of Agxx Intellectual Property Holding GmbH's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.